Apixaban (Eliquis®)

Assessment Status NCPE Assessment Process Complete
Drug Apixaban
Brand Eliquis®
Indication For the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.
Assessment Process
Rapid review commissioned 19/10/2021
Rapid review completed 02/11/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 01/02/2012
NCPE assessment completed 19/06/2012
NCPE assessment outcome The NCPE believe that apixaban is cost effective for the prevention of VTE following total hip replacement and total knee replacement.